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We have analyzed the glycosaminoglycans exposed on the surface of endothelial cells cultured in vitro. The cells were labelled with [“S]sodtum 
sulfate. Chondrottm sulfate, heparan sulfate and dermatan sulfate are the mam sulfated glycosaminoglycans present on the cell surface. They are 
synthesized by endothelial cells. However, the electrophoretic analysis and correspondmg autoradiography of the glycosammoglycans removed 
from the endothelial cell surface shows the presence of heparin-like compound which IS not synthesized by the cells as it is unlabelled by [“S]sodium 
sulfate. We show here that a proteolytic treatment of the commonly used serum for cell culturmg. reveals the presence of an heparin-like 
anticoagulant activity. These results suggest that the endothehal cells bind endogenous heparm-like molecules present in serum. 
Heparm: Glycosammoglycans; Endothelial cell 
1. INTRODUCTION 
One of the remarkable features of the coagulation 
system is its ability to respond rapidly to seal a wound 
site, limiting the blood clotting to the site of the wound. 
During platelet activation and fibrin formation there 
are endogenous mechanisms that tend to limit thrombus 
formation. The known mechanisms are the generation 
of prostacyclin [l], the activation of protein C [2], fibri- 
nolysis [3], and the presence of the naturally occurring 
inhibitor antithrombin III, which is potentiated by the 
presence of heparin [4]. Endothelial cells synthesize hep- 
aran sulfate with high affinity for antithrombin III, 
which can function to accelerate the inactivation of co- 
agulation factors by antithrombin III on the endothelial 
cell surface [5]. We have previously shown that endothe- 
lial cells are able to bind and uptake [3H]heparin added 
to culture medium, and that they also release its low 
molecular weight degradation products, thus indicating 
a metabolism of heparin [6,7]. We have also shown that 
BACE cells contain heparin; however, as heparin ex- 
tracted from these cells is consistently unlabelled with 
[35S]sodium sulfate, we hypothesized that heparin con- 
tained in BACE cells comes from serum [6]. In this 
paper we have analyzed the glycosaminoglycans 
(GAGS) removed by trypsin from endothelial cell sur- 
face and those present in the medium of BACE cells 
after labelling with [35S]sodium sulfate. The results indi- 
cate that endothelial cells bind on their surface heparin- 
like molecules which are not synthesized by the cells. In 
addition, we show that serum contains an heparin-like 
anticoagulant activity, which can be measured by 
thrombin time assay after an extensive proteolysis. We 
discuss the exposure of heparin related compounds de- 
rived from serum on the endothelial cell surface as it 
relates to the control of clotting extension and the repair 
of the injured vessel wall. 
2. MATERIALS AND METHODS 
Endothelial cells isolated from bovine adrenal capillary endothe- 
hum (BACE) kindly provided by Dr. M. Ziche, Dept. of Pharmacol- 
ogy, University of Florence, Italy, have been described in our previous 
report [6]. BACE cells were grown in DMEM plus 10% foetal calf 
serum (Grand Island Biological Co., Gtbco, Grand Island, NY. USA). 
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Cells were labelled with [“S]sodium sulfate (New England Nuclear. 
Boston, MA, USA) as described in [6]. Cells were washed 5 times in 
phosphate-buffered saline, treated with 0.25% trypsin (Gibco, USA) 
for 5 mm at 37°C and centrifuged at 200 x g x 10 min. Medium and 
trypsinate were lyophtlized before isolatmg GAGS followmg the mod- 
ified Folch-extraction procedure as previously described [6]. The 
GAGS extracted m aqueous phases were fractionated stepwise on 
DEAE-Sephacel (Pharmacia, Uppsala, Sweden). Fractions eluted 
with 0.6 M and 2.0 M NaCl were dialyzed against distilled water, 
concentrated and analyzed on cellulose acetate electrophoresis at pH 
1.0 [8] and at pH 5.0 [9]. Standard chondroitin sulfate A (CSA). 
chondroitin sulfate C (CCS) and dermatan sulfate (DS) were obtained 
from Seikagaku Kogyo Co., Tokyo: hyaluronic acid (HA) was from 
Stgma Chem. Co.. St. Louis, MO and heparan sulfate (HS) from 
Upjohn International Inc., Kalamazoo, MI. Standard heparin (HP 
756. 150 IU/mg) was a kind gift of Prof. Pietro Bianchini, Opocrm 
Research Laboratories, Modena. Italy. [‘HI-labelled heparm was ob- 
tamed from New England Nuclear, Boston, MA. USA. Nitrous acid 
treatment was performed directly on cellulose acetate sheet [9]. Cellu- 
lose acetate electrophoreses were subjected to direct autoradiography. 
In addition, aliquots of the ‘S-labelled GAGS extracted both from 
BACE cells and trypsinate were combined, mixed with standard 
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GAGS (CSA and HP 756) and applied to a column of DEAE cellulose 
(DE-52. Whatman) (1 cm x 4 cm). The column was washed extensively 
with 0.05 M LiCl in 0.05 M acetate buffer, pH 4.0, and was then eluted 
with a linear gradient extending from 0.05 to 1.5 M LtCl in the same 
acetate buffer. Fractions of 2.0 ml were collected and analyzed for 
‘S-radtoacttvtty and uromc actd. Hexuronic acid was measured by the 
carbazole method of Bitter and Muir [lo]. 
Aliquots of I ml of foetal calf serum were submttted to proteolytic 
digestion as described elsewhere [l I]. Briefly, papam (EC 3.4.22.2; 
Calbiochem) was added for 13 h at 60°C. Samples were then boiled 
and, at intervals of 24 h. the following enzymes. each at final concen- 
tration of 1 mg/ml. were added sequentially: trypsm (EC 3.4.31.4). 
chymotrypsin (EC 3.4 21.1). collagenase (EC 3 4.24.3) (Stgma Chem. 
Co.) and pepsm (EC 3.4.23 1) (Boehrmger-Mannheim). Samples were 
botled at the end of each mcubatton. Samples were centrifuged at 
3000 x I: x 10 mm and the thrombin time assay was performed on 100 
~1 of the clear supernatants [I I]. For the quantnattve evaluatton of the 
anttcoagulant activity thrombm time assay was performed in the pres- 
ence of increasing concentrattons of standard heparin 
3. RESULTS 
Fig. 1 shows the lectrophoresis of the complex mix- 
ture of GAGS extracted from BACE cells and trypsinate 
analyzed on cellulose acetate electrophoresis at pH 5.0 
and the corresponding autoradiography. GAGS co-mi- 
grating with standard chondroitin sulfate A, dermatan 
sulfate and heparan sulfate are clearly identified. These 
GAGS are actively synthesized by the cells as shown in 
the corresponding autoradiography. The presence of 
N-sulfated GAGS is demonstrated by nitrous acid treat- 
ment performed on trypsin-removable GAGS (Fig. 3). 
Chondroitin sulfate A and heparan sulfate are the main 
GAGS synthesized by BACE cells and are exposed on 
the cell surface. Dermatan sulfate, which is resistant to 
treatment with nitrous acid is also present. However, 
this type of analysis does not allow separation between 
heparan sulfate and the fractions of heparin which are 
not precipitated in barium acetate (so-called fast-mov- 
ing heparin fraction) [12]. as demonstrated by the au- 
toradiography of the standard mixture containing ‘H- 
labelled heparin shown in Fig. 1. The presence of hepa- 
St a b St1 al bi 
Fig. 1. Cellulose acetate electrophoresis of GAGS from BACE cells 
and trypsinate. (A) The electrophorettc run at pH 5.0 m 0.1 M barmm 
acetate of GAGS extracted from BACE cells (a) and trypsmate (b). (B) 
This is the corresponding autoradtography St, standard mtxture: 
CSC, chondrottm sulfate C; CSA. chondrottm sulfate A: HA. hy- 
aluronic acid. DS. dermatan sulfate: HS, heparan sulfate: HP. fast 
moving ‘H-labelled heparm. Lanes St,, a, and b, correspond to lanes 
4. DISCUSSION 
In vivo and in vitro studies indicated that endothelial 
cells bind, internalize and degrade exogenous heparin 
[ 13.141. Binding has been implicated in heparin’s phar- 
macokinetics (151. 
St through b on the sheet. In this paper we demonstrate that endothelial cells 
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Fig. 2. Nitrous acid treatment of trypsin-removable GAGS from 
BACE cells. Cellulose acetate electrophoresis of trypsin-removable 
GAGS before (A) and after treatment wtth nitrous actd (B). Run at 
pH 5.0 m 0.1 M barmm acetate. St, Stl. standard mixture; a, a,% 
trypsm-removable GAGs The abbrevtattons for standard GAGS are 
as m Fig. 1. 
rin in a GAG mixture can be better recognized with an 
electrophoretic analysis performed at pH 1.0. 
Fig. 3 shows the lectrophoretic pattern and the cor- 
responding autoradiography of GAGS extracted from 
[35S]sodium sulfate-labelled BACE cells, medium, and 
trypsinate at pH 1.0. The autoradiography clearly 
shows that GAGS which co-migrate with standard hep- 
arin are the only unlabelled compounds. We have fur- 
ther analyzed the ‘“S-labelled GAGS extracted both 
from cells and trypsinate by an ion-exchange chroma- 
tography on DE-52 eluted with a linear gradient of 
LiCl. As shown in Fig. 4, only a small portion of the 
“S-labelled GAGS is eluted later than a chondroitin 
sulfate standard, but ahead of heparin. whereas the 
main fraction of the “S-1abelled GAG is co-eluting with 
standard chondroitin sulfate. These results demonstrate 
that BACE cells do not synthesize heparin. However, 
the unlabelled highly-sulfated compound co-migrating 
with standard heparin in cellulose acetate electrophore- 
sis shown in Fig. 3 was also extracted from the culture 
medium containing 10% foetal calf serum. We show in 
Fig. 5 that the supernatant of the proteolytically di- 
gested serum. produces a delay in thrombin time which 
corresponds to 1.2 pug/ml of standard heparin. Taken 
together. these results suggest that BACE cells bind the 
endogenous heparin present in the serum on their sur- 
face. 
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Fig. 3. Analysis of GAGS extracted from BACE cells, medium and trypsinate by cellulose acetate electrophoresis at pH 1 .O. BACE cells were labelled 
with [?S]sodium sulfate and treated with trypsin as described. GAGS from medium. trypsinate and cells were extracted and submitted to 
ion-exchange chromatography on DEAE-Sephacel. (A) Cellulose acetate electrophoresls at pH 1 .O: (a,c,e) GAGS eluted at 0.6 M NaCl fraction 
extracted from medium (a), trypsinate (c). and cells (e): (b,d.f) GAGS eluted in 2 0 M fraction extracted from medium (b), trypsinate (d) and cells 
(f); (g) standard heparm (HP 756) mixed with ‘H-labelled heparin. (B) This is the corresponding autoradiography of the cellulose acetate sheet in 
(A): lanes a,. b,. c,% d,, e,. f, and g, correspond to lanes a through g on the sheet. 
expose on their surface endogenous heparin-like com- 
pounds. It is well known that endothelial cells synthe- 
size heparan sulfate with high affinity for antithrombin 
III [5]. However, we show here that endothelial cells 
expose heparin-like molecules which are not synthesized 
by the cells, but they are instead derived from serum. In 
a previous paper we described how heparin can be ex- 
tracted from human plasma or serum using a modified 
Folch-extraction procedure [ 161. Unfortunately this 
method yielded results difficult to reproduce: further 
results lead us to suggest that interactions with proteins 
are responsible for the difficulty in isolating endogenous 
heparin from plasma or serum [17]. According to this 
hypothesis, a proteolytic digestion of plasma proteins 
reveals the presence of an heparin-like anticoagulant 
activity in plasma [ll]. In this paper we describe that 
very similar results are obtained on foetal calf serum 
HP 
used for cell cultures. These results suggest that heparin 
bound on the cell surface is derived from serum. We 
have previously shown how activated platelets release 
heparin [18]. However, heparin-like molecules are also 
present in circulating plasma under an undetectable 
form [16,17], probably due to the interactions between 
heparin and proteins [19]. Whatever the origin of these 
compounds, whether platelets or the plasmatic com- 
partment undergoing clotting cascade activation, this 
binding can represent an important mechanism to limit 
blood clotting at the areas of endothelial cell damage 
avoiding clot propagation on uninjured endothelium. 
Furthermore, heparin stimulates endothelial cell prolif- 
eration by interacting. and increasing the effect of fi- 
broblast growth factor [20]. It has recently been re- 
ported that endothelial cells synthesize fibroblast 
growth factor which they sequester in their matrix [21]. 
Thus. a binding of heparin after clotting on undamaged 
endothelium could participate in vessel wall repair by 
stimulating endothelial cell regeneration. 
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Fig. 4. Ion-exchange chromatography on DEAE-cellulose of “S-la- 
belled GAGS from BACE cells and trypsinate. Ahquots of the ‘5S- 
labelled GAGS extracted both from cells and trypsmate were com- 
bined. mixed with standard heparm and chondromn sulfate A and 
applied to a column of DEAE-cellulose (DE-52). The elution was 
performed as described in sectlon 2. The arrows on the top of the 
figure mdicate the peak elutlon positlons of chondroltm sulfate (CSA) 
and heparin (HP) standards. (+). the LKl linear gradlent. 
Fig. 5 Thrombin time assay. The thrombin time assay was performed 
on pooled human plasma m the presence of different concentrations 
of standard heparm (A) or m the presence of different amounts (70, 
80 and 100 ,~l) of the proteolytlcally dlgested serum (B). 
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